CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data

• The data were presented at the American Urological Association (AUA) 2026 Annual Meeting.
• Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug.
• If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.

Shares of Candel Therapeutics Inc. (CADL) rose 3% in after-hours trading on Friday following the release of extended follow-up data from its pivotal late-stage trial of CAN-2409 in intermediate- to high-risk localized prostate cancer.

The company reported that, after a median follow-up of 58 months, CAN-2409 delivered a statistically significant 39% improvement in prostate cancer-specific disease-free survival versus placebo in the intention-to-treat population. In the intermediate-risk subgroup — which made up 85% of the 745-patient trial — the benefit was even stronger, with a 41% reduction in risk of recurrence, along with notable improvements in time to biochemical failure, time to metastasis, and time to next anti-cancer therapy, the firm said.

The data, which reinforces the potential of the drug to reduce the risk of tumor recurrence, were presented at the American Urological Association (AUA) 2026 Annual Meeting.

Plan Ahead

Candel plans to submit a Biologics License Application to the FDA in the fourth quarter of 2026 for the drug. If approved, CAN-2409 would be the first new therapy added to standard radiotherapy for localized prostate cancer in more than 20 years, the company said.

What Did Phase 3 Results Show?

In December 2024, Candel reported positive late-stage results for CAN-2409. The study met its primary endpoint, showing that patients who received the drug along with standard treatment stayed disease-free longer than those on standard care alone.

The drug has already received Fast Track and Regenerative Medicine Advanced Therapy designations from the U.S. Food and Drug Administration.

How Did CADL Retail Traders React?

On Stocktwits, retail sentiment around CADL rose from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.

CADL stock has risen 72% over the past 12 months.   

Read More: DAL, M, AMZN, V, And UNH Stocks In Focus As Berkshire Rejigs Portfolio

For updates and corrections, email newsroom[at]stocktwits[dot]com.